MX2016016251A - Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa. - Google Patents

Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa.

Info

Publication number
MX2016016251A
MX2016016251A MX2016016251A MX2016016251A MX2016016251A MX 2016016251 A MX2016016251 A MX 2016016251A MX 2016016251 A MX2016016251 A MX 2016016251A MX 2016016251 A MX2016016251 A MX 2016016251A MX 2016016251 A MX2016016251 A MX 2016016251A
Authority
MX
Mexico
Prior art keywords
lymphocytes
sample
expansion
interleukin
clinically relevant
Prior art date
Application number
MX2016016251A
Other languages
English (en)
Inventor
Maeurer Markus
Original Assignee
Polybiocept Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53546572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016016251(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polybiocept Ab filed Critical Polybiocept Ab
Publication of MX2016016251A publication Critical patent/MX2016016251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464404—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a una composición para expandir linfocitos que comprende al menos dos tipos de citocinas seleccionadas entre interleucina 2 (IL-2), interleucina 15 (IL-15) e interleucina 21 (IL-21). También se refiere a un método para preparar una población de linfocitos clínicamente relevantes, que comprende las etapas de: obtener una muestra corporal de un mamífero, en particular una muestra de tejido o fluido corporal, que comprende al menos un linfocito y opcionalmente separar las células de la muestra corporal, cultivar la muestra corporal in vitro para expandir y/o estimular linfocitos en la muestra, en donde el cultivo comprende usar IL-2, IL-15 y/o IL-21, y opcionalmente determinar la presencia de linfocitos clínicamente relevantes en la muestra cultivada. La presente invención también se refiere a una inmunoterapia y a una población de linfocitos clínicamente relevantes.
MX2016016251A 2014-06-11 2015-06-11 Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa. MX2016016251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102014211167 2014-06-11
PCT/EP2015/063108 WO2015189357A1 (en) 2014-06-11 2015-06-11 Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy

Publications (1)

Publication Number Publication Date
MX2016016251A true MX2016016251A (es) 2017-07-11

Family

ID=53546572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016251A MX2016016251A (es) 2014-06-11 2015-06-11 Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa.

Country Status (17)

Country Link
US (1) US20170107490A1 (es)
EP (2) EP3154567B1 (es)
JP (3) JP7413639B2 (es)
KR (1) KR102441940B1 (es)
CN (1) CN106574244B (es)
AU (1) AU2015273501B2 (es)
CA (1) CA2951749A1 (es)
ES (1) ES2855475T3 (es)
IL (1) IL249409B (es)
MX (1) MX2016016251A (es)
MY (1) MY180750A (es)
PT (1) PT3154567T (es)
RU (1) RU2739770C2 (es)
SG (1) SG11201610350SA (es)
UA (1) UA123821C2 (es)
WO (2) WO2015189356A1 (es)
ZA (1) ZA201700211B (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
MY198084A (en) * 2015-10-30 2023-07-31 Cancer Research Tech Ltd Expansion of non-haematopoietic tissue-resident ()()t cells and uses of these cells
EP3202784A1 (en) 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
WO2017190684A1 (zh) * 2016-05-06 2017-11-09 王牧林 白细胞介素组合及其用途
GB201608060D0 (en) * 2016-05-09 2016-06-22 Univ Birmingham Method of culturing T cells
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
IL264104B2 (en) 2016-07-07 2024-08-01 Iovance Biotherapeutics Inc PD-L1 binding proteins and methods of using them
EP3516043A1 (en) * 2016-09-26 2019-07-31 Tessa Therapeutics Pte. Ltd. T cell expansion method
MD3532607T2 (ro) 2016-10-26 2024-07-31 Iovance Biotherapeutics Inc Restimularea limfocitelor infiltrante în tumori crioconservate
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
JP7125392B2 (ja) 2016-11-17 2022-08-24 アイオバンス バイオセラピューティクス，インコーポレイテッド レムナント腫瘍浸潤リンパ球並びにそれを調製及び使用する方法
WO2018102761A1 (en) * 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
WO2018115146A1 (en) 2016-12-21 2018-06-28 Danmarks Tekniske Universitet Antigen presenting scaffolds for immune-cell manipulation
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
US11357841B2 (en) 2017-01-06 2022-06-14 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
EP3388836B1 (en) 2017-04-12 2020-11-25 polybiocept GmbH Methods for predicting survival and treatment susceptibility of glioblastoma multiforme (gbm) patients using cytokine profiles
EP3388073A1 (en) 2017-04-12 2018-10-17 polybliocept GmbH Targeting mesothelin in brain cancer
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
EP3622055A1 (en) 2017-05-10 2020-03-18 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP3635097A1 (en) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
AU2018328209A1 (en) 2017-09-05 2020-04-23 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CN107460167B (zh) * 2017-09-21 2020-12-15 山东省齐鲁细胞治疗工程技术有限公司 一种无滋养细胞的nk细胞的扩增方法
EP3691662A4 (en) * 2017-10-06 2021-05-12 The University of Chicago T-LYMPHOCYTES SCREENING FOR CANCER-SPECIFIC ANTIGENS
US20200338125A1 (en) * 2017-11-06 2020-10-29 Ludwig Institute For Cancer Research Ltd Method for expansion of lymphocytes
SG11202004457XA (en) * 2017-11-17 2020-06-29 Iovance Biotherapeutics Inc Til expansion from fine needle aspirates and small biopsies
CA3083118A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
CN108165529B (zh) * 2017-12-28 2021-07-16 北昊干细胞与再生医学研究院有限公司 中枢记忆性t细胞体及其外培养方法
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
MY197176A (en) 2018-02-01 2023-05-30 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
CN110101843A (zh) * 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 一种抗肿瘤蛋白质及其应用
JP2021512962A (ja) * 2018-02-13 2021-05-20 アイオバンス バイオセラピューティクス，インコーポレイテッド アデノシンａ２ａ受容体アンタゴニストによる腫瘍浸潤性リンパ球（ｔｉｌ）の拡大培養並びにｔｉｌ及びアデノシンａ２ａ受容体アンタゴニストの治療的組み合わせ
FI3775165T3 (fi) 2018-03-29 2024-07-01 Iovance Biotherapeutics Inc Prosesseja kasvaimiin infiltroituvien lymfosyyttien tuottamiseksi ja niiden käyttö immunoterapiassa
CN108546679B (zh) * 2018-04-23 2021-04-16 北京翊博普惠生物科技发展有限公司 在体外大量扩增人类成熟高活性树突状细胞的方法及其应用
MA52533A (fr) 2018-04-27 2021-03-03 Iovance Biotherapeutics Inc Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2020021114A1 (en) 2018-07-27 2020-01-30 Nordwest Polybiocept Bioscience Gmbh Method for the treatment of a tumor patient with adoptive t cell immunotherapy
SG11202101015WA (en) * 2018-07-31 2021-02-25 Polybiocept Gmbh Production and selection of tumor uber reactive immune cells (turics)
EP3844265A2 (en) * 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
BR112021003678A2 (pt) 2018-09-20 2021-05-18 Iovance Biotherapeutics, Inc. métodos para criopreservar tecido de tumor, para fabricar, para preparar e para expandir linfócitos infiltrantes de tumor, para tratar um indivíduo com câncer e para tratar câncer para um indivíduo humano, e, fragmento de tumor criopreservado .
JP2022506508A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
PE20211292A1 (es) * 2018-11-05 2021-07-20 Iovance Biotherapeutics Inc Procesos para la produccion de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
BR112021008266A2 (pt) 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Métodos para expandir linfócitos infiltrantes de tumor em uma população terapêutica de linfócitos infiltrantes de tumor e para tratar um sujeito com câncer, e, população terapêutica de linfócitos infiltrantes de tumor
CN112969469A (zh) 2018-11-05 2021-06-15 艾欧凡斯生物治疗公司 抗pd-1抗体难治性nsclc患者的治疗
BR112021008963A2 (pt) 2018-11-08 2021-09-14 Neximmune, Inc. Composições de célula t com propriedades fenotípicas melhoradas
MX2021005481A (es) * 2018-11-08 2021-11-04 Gammadelta Therapeutics Ltd Metodos para aislar y expandir celulas.
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
EP3898941A4 (en) * 2018-12-18 2022-02-23 Beth Israel Deaconess Medical Center, Inc. GENERATION OF ORGANOID-PRIMED T-CELLS WITH MEMORY PHENOTYPE
JP2022514023A (ja) 2018-12-19 2022-02-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
CN113454209A (zh) * 2018-12-19 2021-09-28 大学健康网络 通用型双阴性t细胞的制备和治疗用途
CA3131879A1 (en) * 2019-02-20 2020-08-27 Rutgers, The State University Of New Jersey Expansion of natural killer and chimeric antigen receptor-modified cells
CN113574170A (zh) * 2019-03-15 2021-10-29 特拉百思特股份有限公司 细胞组合物、其生产方法及包含其的用于预防或治疗特应性疾病的药物组合物
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020243416A2 (en) * 2019-05-31 2020-12-03 Beth Israel Deaconess Medical Center, Inc. Methods for generation of tumor organoid-fished t cells and identification of anti-tumor t cell receptors
KR20210048161A (ko) 2019-10-23 2021-05-03 엘지전자 주식회사 기액 분리기 및 이를 포함하는 공기 조화기
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN110628717B (zh) * 2019-10-28 2020-10-30 上海科医联创生物科技有限公司 一种浸润性t细胞的培养方法
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
MX2022007598A (es) 2019-12-20 2022-09-23 Instil Bio Uk Ltd Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos.
IL297442A (en) 2020-04-22 2022-12-01 Iovance Biotherapeutics Inc Systems and methods for coordinating production of cells for patient-specific immunotherapy
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
TW202208617A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
GB202006989D0 (en) 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
EP4239059A4 (en) * 2020-11-19 2024-05-15 Suzhou Grit Biotechnology Co., Ltd. METHOD FOR CULTIVATION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
CN112442482A (zh) * 2020-12-11 2021-03-05 北京双因生物科技有限公司 一种nkt细胞培养方法
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
EP4263808A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
US20240269280A1 (en) 2020-12-18 2024-08-15 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
US20240110152A1 (en) 2020-12-31 2024-04-04 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
CN114763530A (zh) * 2021-01-15 2022-07-19 上海细胞治疗集团有限公司 一种诱导和制备til细胞的方法
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
AR126323A1 (es) 2021-03-05 2023-10-04 Iovance Biotherapeutics Inc Composiciones para el almacenamiento de tumores y cultivos celulares
CN113005084A (zh) * 2021-03-17 2021-06-22 山西怀瑾基业生物科技有限公司 一种将体外富集的pbmc扩增活化cd8+t细胞群的方法
CN113005085A (zh) * 2021-03-18 2021-06-22 南方医科大学南方医院 一种新型的原发性肝癌肿瘤浸润淋巴细胞的培养及体外扩增方法
TW202304480A (zh) 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
GB202105113D0 (en) 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US20240197873A1 (en) * 2021-04-23 2024-06-20 Suzhou Grit Biotechnology Co., Ltd. Modified tumor-infiltrating lymphocyte and use thereof
CN113215099B (zh) * 2021-04-28 2022-11-22 广东康盾创新产业集团股份公司 一种til细胞扩增培养基及其使用方法
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
DE102021002748A1 (de) 2021-05-27 2022-12-01 Zellwerk Gmbh Verfahren zur Herstellung von Tumor-infiltrierten T-Lymphozyten (TIL) und deren Verwendung als Zell-Therapeutika für die Behandlung humaner Tumoren
WO2023278335A1 (en) * 2021-06-28 2023-01-05 Cytoimmune Therapeutics, Inc. Methods and compositions for cell expansion
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
KR20240109615A (ko) 2021-09-09 2024-07-11 이오반스 바이오테라퓨틱스, 인크. Pd-1 talen 녹다운을 사용한 til 생성물의 생성 방법
EP4404969A1 (en) 2021-09-24 2024-07-31 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
AR127482A1 (es) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
EP4435095A1 (en) * 2021-11-17 2024-09-25 Sungkwang Medical Foundation Improved method for preparing tumor-infiltrating lymphocyte
CN114107201B (zh) * 2021-11-29 2023-04-21 华东师范大学 一种CD3+TCRVα7.2+T细胞培养基和扩增培养方法
KR20230105166A (ko) 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
WO2023138598A1 (zh) * 2022-01-19 2023-07-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞在疾病治疗中的用途
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
CN114426585B (zh) * 2022-02-15 2023-10-03 广东香雪干细胞再生医学科技有限公司 融合蛋白及其表达细胞株与应用
CN115433713B (zh) * 2022-03-03 2023-10-27 中山大学孙逸仙纪念医院深汕中心医院 一种自体肿瘤引流淋巴结淋巴细胞的制备方法及其应用
GB202204926D0 (en) 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024055017A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024107750A1 (en) * 2022-11-15 2024-05-23 Immunitybio, Inc. Compositions and methods of mait cell activation
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985656A (en) * 1986-06-12 1999-11-16 The Board Of Trustees Of The Leland Stanford Junior University Suppressor and progenitor cells
WO2007071390A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating malignant melanoma
WO2007071409A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating colon cancer
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US20080131396A1 (en) * 2006-12-04 2008-06-05 Cel-Sci Corp. Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor
CN101348521B (zh) * 2008-09-04 2011-06-01 江苏省中医药研究院 人b淋巴细胞刺激因子受体的氨基酸模拟表位及其应用
KR101077912B1 (ko) * 2008-10-24 2011-10-31 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
AU2009314704A1 (en) * 2008-11-13 2010-05-20 Instituto De Medicina Molecular Foxp3+ natural kiler T-cells and the treatment of immune related diseases
JPWO2011021503A1 (ja) 2009-08-17 2013-01-24 国立大学法人 東京大学 一過性生着ｃｔｌを含む医薬品組成物
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
CN103756964B (zh) 2013-12-30 2016-02-24 天津斯坦姆生物科技有限公司 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法
CN103849599B (zh) * 2014-03-18 2016-09-14 康思葆（北京）生物技术有限公司 一种高效扩增自体nk细胞的培养基及培养方法
US10081135B2 (en) * 2014-04-02 2018-09-25 Ge Healthcare Bio-Sciences Ab Fuser and sealer integrated system
WO2015157636A1 (en) * 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
WO2015189301A1 (en) * 2014-06-10 2015-12-17 Polybiocept Ab Culture medium for cellular immunotherapy

Also Published As

Publication number Publication date
WO2015189356A1 (en) 2015-12-17
SG11201610350SA (en) 2017-01-27
CN106574244A (zh) 2017-04-19
BR112016028996A2 (pt) 2018-01-30
RU2739770C2 (ru) 2020-12-28
ES2855475T3 (es) 2021-09-23
RU2016151694A (ru) 2018-07-13
AU2015273501A1 (en) 2017-01-12
ZA201700211B (en) 2018-07-25
EP3838288A1 (en) 2021-06-23
AU2015273501B2 (en) 2021-01-21
UA123821C2 (uk) 2021-06-09
NZ727479A (en) 2023-11-24
EP3154567B1 (en) 2020-11-25
JP2017525754A (ja) 2017-09-07
MY180750A (en) 2020-12-08
IL249409A0 (en) 2017-02-28
EP3154567A1 (en) 2017-04-19
JP2021113200A (ja) 2021-08-05
JP2023178302A (ja) 2023-12-14
KR102441940B1 (ko) 2022-09-08
US20170107490A1 (en) 2017-04-20
KR20170031139A (ko) 2017-03-20
RU2016151694A3 (es) 2019-01-23
IL249409B (en) 2020-06-30
WO2015189357A1 (en) 2015-12-17
CN106574244B (zh) 2022-01-07
PT3154567T (pt) 2021-03-03
CA2951749A1 (en) 2015-12-17
JP7413639B2 (ja) 2024-01-16
JP7452929B2 (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
MX2016016251A (es) Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa.
MX2022011003A (es) Expansion de celulas t gamma-delta residentes en tejido no hematopoyetico y usos de estas celulas.
EP4286511A3 (en) Method to treat cancer with engineered t-cells
MX2021008143A (es) Metodos para cosechar cultivos de celulas de mamifero.
EP3612623A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE CULTURE DENSITY OF A CELLULAR BIOMASS IN A CULTURE INFRASTRUCTURE
MX2021005481A (es) Metodos para aislar y expandir celulas.
MY161389A (en) Method for amplifying nk cells
EP2998026A3 (en) Collector architecture layout design
CL2016000433A1 (es) Sistema y métodos para la propagación continua y producción en masa de hongos micorrícicos arbusculares en cultivo líquido
ATE544848T1 (de) Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)
EP1904624A4 (en) METHOD FOR THE CULTIVATION AND REPRODUCTION OF HEMATOPOETIC STEM CELLS AND PRECURSOR CELLS USING HUMAN ENDOMETRIUM CELLS
PH12021551038A1 (en) Methods for isolating and expanding cells
BR112018004454A2 (pt) nova subpopulação de tregs cd8+cd45rcbaixo e seu uso
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
WO2015108944A3 (en) Stem cell-derived hepatocytes in co-culture and uses thereof
NZ749136A (en) Methods of immunotherapy
IL288819A (en) Methods for cell culture and preparations for antibody production
MY193535A (en) Cell culture methods
EP3967753A4 (en) PROCESS FOR CULTIVATION OF ALLOGOUS IMMUNITY CELLS, IMMUNITY CELL CULTURE OBTAINED THEREBY AND IMMUNITY CELL THERAPEUTIC THEREFORE
WO2021101273A3 (ko) 조절 t 세포 배양용 조성물 및 이의 용도
EP4248991A3 (en) Methods and materials for expanding antigen-specific t cells in culture
EP3892721A4 (en) METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES
EP3950934A4 (en) METHOD FOR CULTIVATING A CELL POPULATION AND USE THEREOF
RU2012103822A (ru) Способ генерации антиген-специфических цитотоксических клеток с активностью против клеток рака яичника
MX2018001076A (es) Medio de cultivo celular exento de suero.